background
grow
evid
communityacquir
respiratori
viru
carv
increas
risk
pulmonari
invas
fungal
diseas
ifd
allogen
hematopoiet
stem
cell
transplant
allohsct
set
date
lack
knowledg
regard
risk
factor
rf
well
critic
period
subsequ
onset
ifd
carv
infect
allohsct
recipi
prospect
longitudin
observ
carv
survey
analyz
effect
carv
subsequ
ifd
develop
adult
allohsct
recipi
diagnos
carv
episod
decemb
decemb
multiplex
pcr
panel
assay
use
test
carv
respiratori
specimen
find
twentynin
allohsct
recipi
develop
ifd
carv
episod
median
time
ifd
onset
day
rang
day
day
first
carv
detect
gener
estim
equat
model
identifi
risk
factor
ifd
atgbas
condit
regimen
odd
ratio
confid
interv
ci
p
carv
lower
respiratori
tract
diseas
ci
p
carv
infect
first
year
transplant
ci
p
corticosteroid
carv
ci
p
conclus
allohsct
recipi
condit
atg
corticosteroid
therapi
time
carv
lrtd
first
year
transplant
may
requir
close
monitor
subsequ
ifd
pulmonari
invas
fungal
diseas
ifd
relev
caus
morbid
mortal
allogen
hematopoiet
stem
cell
transplant
allohsct
set
ifd
allohsct
mainli
invas
aspergillosi
ia
includ
factor
associ
profound
immunosuppress
statu
durat
neutropenia
engraft
use
durat
glucocorticosteroid
therapi
type
donor
baselin
diseas
recipi
age
graftversushost
diseas
gvhd
howev
grow
awar
evid
communityacquir
respiratori
viru
carv
also
increas
risk
ia
immunocompromis
healthi
patient
primarili
limit
influenza
infect
allohsct
recipi
suffer
annual
lifelong
exposur
carv
infect
fact
infect
allohsct
common
around
obvious
everi
allohsct
recipi
carv
infect
risk
develop
ifd
date
limit
data
regard
true
rate
ifd
rf
specif
respiratori
viru
infect
critic
period
ifd
develop
carv
infect
allohsct
recipi
current
studi
come
prospect
longitudin
observ
epidemiolog
survey
carv
infect
complic
allohsct
recipi
upper
urtd
andor
lower
respiratori
tract
diseas
lrtd
symptom
allohsct
report
herein
incid
rate
characterist
rf
ifd
seri
consecut
allohsct
recipi
molecularproven
carv
infect
conduct
prospect
longitudin
studi
carv
infect
adult
year
allohsct
recipi
two
transplant
center
carv
survey
methodolog
previous
describ
detail
elsewher
briefli
center
develop
prospect
carv
survey
allohsct
recipi
symptom
suggest
respiratori
viru
infect
irrespect
transplant
date
recipi
urtd
andor
lrtd
symptom
encourag
undergo
detail
respiratori
viru
screen
molecular
test
monitor
viral
shed
neg
first
detect
except
recipi
activ
persist
respiratori
symptom
longer
one
month
case
repeat
pcr
test
rule
acquisit
new
carv
subtyp
carv
found
consid
longlast
carv
episod
clinic
biolog
variabl
time
carv
pcr
test
prospect
record
variabl
includ
transplant
characterist
condit
includ
immunodefici
score
index
isi
hospit
admiss
immunosuppress
drug
presenc
acut
chronic
gvhd
use
antifung
prophylaxi
time
carv
infect
subsequ
onset
ifd
allohsct
recipi
follow
regular
basi
transplant
center
lifelong
studi
protocol
approv
ethic
committe
hospit
universitari
la
fe
refer
code
number
hcuv
januari
februari
antifung
prophylaxi
base
voriconazol
mg
twice
daili
bid
day
day
thereaft
case
activ
gvhd
requir
steroid
therapi
march
antifung
prophylaxi
consist
micafungin
mgday
iv
start
condit
regimen
neutrophil
recoveri
switch
posaconazol
daili
tablet
day
steroid
treat
moderatetosever
gvhd
hlf
januari
decemb
antifung
prophylaxi
base
fluconazol
mgday
start
condit
day
stem
cell
infus
day
voriconazol
mgbid
day
thereaft
day
steroid
januari
antifung
prophylaxi
chang
consist
fluconazol
mgday
condit
day
posaconazol
mgday
thereaft
day
steroid
urtd
consid
recipi
upper
respiratori
symptom
rhinorrhea
sore
sinus
otiti
pharyng
posit
identif
carv
pcr
test
respiratori
sampl
lack
lrtd
symptom
without
sign
pulmonari
infiltr
chest
xray
ct
scan
classifi
lrtd
possibl
confirm
accord
previou
definit
probabl
episod
sinc
perform
bronchoscopi
patient
without
radiolog
evid
pulmonari
involv
defin
carv
urtd
andor
lrtd
episod
follow
guidelin
accord
recommend
episod
consid
resolv
complet
remiss
respiratori
symptom
observ
case
new
onset
respiratori
symptom
detect
viru
prior
carv
episod
along
anoth
newli
emerg
carv
consid
new
covir
infecti
diseas
episod
contrast
case
detect
carv
recipi
longlast
respiratori
symptom
rescreen
followup
test
posit
new
emerg
carv
along
initi
carv
consid
uniqu
covir
carv
infecti
diseas
episod
per
protocol
start
oseltamivir
allohsct
recipi
influenza
infect
provid
respiratori
symptom
resolv
time
microbiolog
result
annual
influenza
vaccin
also
recommend
patient
transplant
center
third
month
follow
allohsct
patient
moderatetosever
gvhd
time
vaccin
program
receiv
gammaglobulin
antithymocyt
globulin
atg
rituximab
within
three
month
flu
vaccin
period
vaccin
administr
remain
physician
discret
respiratori
syncyti
viru
rsv
human
parainfluenza
viru
hpiv
manag
accord
intervent
protocol
briefli
oral
ribavirin
given
load
dose
maximum
daili
dose
mgkg
resolut
respiratori
symptom
recipi
lrtd
caus
rsv
hpiv
wherea
patient
urtd
must
isi
point
andor
risk
factor
accord
ecil
guidelin
andor
present
one
coinfect
viru
es
start
ribavirin
routin
prophylact
intraven
immunoglobulin
g
kg
given
igg
serum
level
mgdl
definit
european
organ
research
treatment
cancer
mycos
studi
group
eortcmsg
possibl
ifd
episod
consid
final
includ
analys
ifd
date
taken
date
test
yield
diagnosi
ifd
consid
directli
relat
carv
infect
occur
month
follow
either
date
carv
detect
date
recent
carv
detect
case
longlast
activ
respiratori
symptom
viral
shed
sever
consecut
pcr
test
detect
carv
recipi
probableproven
ifd
prior
develop
carv
episod
consid
carvrel
ifd
includ
analys
acut
graftversushost
diseas
agvhd
defin
accord
standard
criteria
carv
test
perform
three
rtpcr
multiplex
platform
two
describ
detail
elsewher
briefli
luminex
xtag
rvp
fast
assay
luminex
molecular
diagnost
clart
pneumovir
dna
array
assay
genomica
use
hcuv
hlf
respect
hlf
juli
onward
carv
screen
allohsct
recipi
perform
biofir
filmarray
respiratori
panel
week
day
stem
cell
infus
hospit
discharg
weekli
basi
thereaft
day
outpati
visit
receiv
steroid
treat
gvhd
afterward
gm
also
screen
bronchoalveolar
lavag
fluid
primari
endpoint
current
studi
determin
ifd
incid
rf
allohsct
recipi
prior
document
carv
urtd
andor
lrtd
secondari
endpoint
includ
analysi
carvrel
ifd
characterist
effect
overal
surviv
os
categor
variabl
frequenc
compar
use
test
fisher
exact
test
wherea
mannwhitney
u
test
use
compar
differ
median
gener
estim
equat
gee
use
assess
associ
clinic
biolog
rf
carvrel
ifd
method
use
analyz
cluster
data
episod
group
within
patient
gee
fit
margin
mean
model
asymptot
normal
consist
estim
correct
specif
margin
mean
two
differ
model
carri
current
studi
one
evalu
rf
ifd
overal
carv
limit
lower
respiratori
respons
variabl
ifd
factor
follow
atg
part
condit
x
carv
lrtd
x
allo
cmv
statu
x
moreov
bj
random
effect
associ
individu
j
sij
experiment
error
consid
random
independ
method
best
model
select
quasilikelihood
independ
model
criterion
qic
method
one
hundr
fortytwo
recipi
carv
episod
recipi
carv
episod
threehundr
ninetyfour
carv
episod
limit
urtd
wherea
lrtd
involv
possibl
lrtd
proven
lrtd
antivir
therapi
oseltamivir
ribavirin
given
carv
episod
tabl
summar
common
carv
type
rate
urtd
lrtd
allohsct
recipi
develop
ifd
within
two
month
carv
episod
median
day
rang
day
day
carv
diagnosi
five
case
ifd
diagnos
median
day
rang
day
initi
carv
diagnosi
howev
case
longlast
respiratori
symptom
repeat
pcr
test
detect
carv
subtyp
two
month
diagnosi
ifd
ifd
involv
lung
case
diagnost
ia
meet
criteria
probabl
n
proven
n
probabl
ia
case
gm
index
blood
n
andor
bal
n
threshold
valu
gee
model
rf
ifd
overal
carv
episod
lrtd
shown
tabl
order
identifi
transplant
carv
circumst
relat
ifd
includ
evalu
recipientepisod
pair
develop
ifd
carv
associ
wors
os
three
month
carv
diagnosi
os
carv
episod
develop
ifd
vs
ifd
p
howev
os
allohsct
recipi
lrtd
develop
ifd
similar
without
ifd
vs
respect
p
figur
b
studi
show
overal
ifd
rate
allohsct
recipi
wherea
rate
accord
overal
carv
infecti
episod
carv
episod
gee
analysi
identifi
atg
carv
lrtd
carv
episod
within
first
year
carv
without
ifd
n
immunodefici
score
index
n
anc
l
alc
l
recent
preengraft
allohsct
low
risk
moder
risk
high
risk
characterist
day
day
abbrevi
alc
absolut
lymphocyt
count
allohsct
allogen
hematopoiet
stem
cell
transplant
anc
absolut
neutrophil
count
atg
antithymocyt
globulin
carv
communityacquir
respiratori
viru
gvhd
graftversushost
diseas
ifd
invas
pulmonari
infecti
fungal
diseas
immunosuppress
lrtd
lower
respiratori
tract
diseas
variabl
captur
time
carv
diagnosi
ta
b
l
e
clinic
biolog
characterist
carv
episod
allohsct
recipi
accord
develop
later
invas
pulmonari
infecti
diseas
transplant
corticosteroid
carv
main
rf
ifd
rf
led
stratif
risk
group
statist
signific
differ
ifd
rate
remark
patient
low
risk
none
rf
low
ifd
rate
although
ifd
rate
still
low
recipi
rf
recipi
rf
show
higher
rate
ifd
addit
found
atg
activ
gvhd
carv
episod
first
year
transplant
main
rf
ifd
recipi
carv
lrtd
although
relationship
carv
invas
mold
infect
andor
ia
consist
establish
allohsct
set
true
rate
lateroccur
ifd
recipi
develop
carv
infect
allohsct
known
data
retrospect
seri
report
rate
ifd
carv
allohsct
recipi
rang
howev
ifd
rate
vari
accord
carv
locat
urtd
lrtd
time
carv
diagnosi
presenc
concurr
rf
sens
ifd
rate
recipi
urtd
wherea
lrtd
ifd
rate
even
higher
recipi
develop
carv
lrtd
first
year
stem
cell
infus
data
show
ifd
rate
lower
previous
carv
involv
alter
bronchial
mucosa
pulmonari
defens
mechan
fact
ifd
later
event
seri
recipi
develop
ifd
day
might
explain
neutropenia
enter
potenti
rf
gee
model
contrast
use
atg
import
rf
ifd
find
surpris
sinc
atg
produc
lymphopenia
signific
deferr
tcell
immun
reconstitut
longer
year
stem
cell
infus
atg
previous
identifi
rf
ia
fact
aspergillusspecif
tcell
activ
recogn
signific
regul
activ
pulmonari
inflamm
like
ad
antifung
effector
activ
anoth
potenti
explan
could
atg
seri
mainli
use
context
singl
cbu
transplant
overal
atg
use
procedur
consist
associ
higher
incid
ifd
sourc
hematopoiet
stem
cell
per
protocol
current
seri
recipi
corticosteroid
therapi
receiv
triazol
antifung
prophylaxi
howev
corticosteroid
use
still
associ
increas
risk
ifd
carv
infect
seri
find
complet
unexpect
sinc
well
establish
corticosteroid
increas
risk
ifd
allohsct
recipi
final
develop
invas
pulmonari
ifd
complic
carv
infect
allohsct
neg
effect
outcom
dismal
prognosi
ifd
allohsct
well
character
current
seri
threemonth
allcaus
mortal
significantli
higher
recipi
ifd
fact
highlight
need
effect
diagnost
prevent
strategi
detect
reduc
ifd
sever
immunosuppress
patient
acknowledg
studi
limit
use
differ
antifung
prophylaxi
strategi
time
use
three
differ
pcr
method
differ
minim
analyt
perform
spite
studi
strength
merit
consider
notabl
use
molecular
test
data
collect
prospect
carv
survey
conclus
provid
evid
ifd
carv
infect
signific
show
neg
associ
outcom
allohsct
recipi
rf
may
requir
close
monitor
futur
develop
ifd
would
like
thank
juan
carbonellasin
